Covalon Technologies Ltd. (CVALF)
USD 2.42
(-1.63%)
USD 2.42
(-1.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.55 Million CAD | 56.11% |
| 2022 | -8.1 Million CAD | -627.0% |
| 2021 | 1.29 Million CAD | 131.49% |
| 2020 | -6.63 Million CAD | 35.87% |
| 2019 | -7.61 Million CAD | -485.95% |
| 2018 | 1.86 Million CAD | -5.14% |
| 2017 | 1.97 Million CAD | 176.17% |
| 2016 | -2.86 Million CAD | -428.85% |
| 2015 | -516.55 Thousand CAD | -118.86% |
| 2014 | 2.59 Million CAD | 495.94% |
| 2013 | -691.89 Thousand CAD | 76.49% |
| 2012 | -3.53 Million CAD | 9.55% |
| 2011 | -3.25 Million CAD | -3223.17% |
| 2010 | -1.59 Million CAD | 102.27% |
| 2009 | -4.7 Million CAD | -35.46% |
| 2008 | -3.39 Million CAD | -7.5% |
| 2007 | -3.15 Million CAD | -51.82% |
| 2006 | -2.07 Million CAD | -19.39% |
| 2005 | -1.74 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 1.72 Million CAD | -0.84% |
| 2024 Q1 | -1.23 Million CAD | 53.51% |
| 2024 Q2 | 1.73 Million CAD | 231.14% |
| 2023 Q2 | -488.46 Thousand CAD | -361.83% |
| 2023 Q4 | -2.64 Million CAD | -736.94% |
| 2023 Q3 | -316.44 Thousand CAD | 35.22% |
| 2023 FY | - CAD | 56.11% |
| 2023 Q1 | -105.76 Thousand CAD | 96.98% |
| 2022 Q3 | -1.38 Million CAD | 36.21% |
| 2022 Q4 | -3.5 Million CAD | -151.9% |
| 2022 Q2 | -2.17 Million CAD | -109.59% |
| 2022 Q1 | -1.03 Million CAD | -65.37% |
| 2022 FY | - CAD | -627.0% |
| 2021 Q2 | 821.85 Thousand CAD | 2098.82% |
| 2021 Q1 | 37.37 Thousand CAD | 102.2% |
| 2021 Q3 | 1.44 Million CAD | 76.33% |
| 2021 FY | - CAD | 131.49% |
| 2021 Q4 | -628.67 Thousand CAD | -143.38% |
| 2020 Q4 | -1.69 Million CAD | -295.82% |
| 2020 FY | - CAD | 35.87% |
| 2020 Q2 | -3.4 Million CAD | -418.69% |
| 2020 Q1 | -655.61 Thousand CAD | 78.81% |
| 2020 Q3 | 865.92 Thousand CAD | 125.46% |
| 2019 Q3 | -3.09 Million CAD | -15245.21% |
| 2019 Q2 | 20.41 Thousand CAD | 101.4% |
| 2019 Q1 | -1.45 Million CAD | -167.38% |
| 2019 FY | - CAD | -485.95% |
| 2019 Q4 | -3.09 Million CAD | -0.08% |
| 2018 Q1 | 597.75 Thousand CAD | 82.08% |
| 2018 Q2 | -402.17 Thousand CAD | -167.28% |
| 2018 Q3 | 2.32 Million CAD | 677.39% |
| 2018 Q4 | -543.64 Thousand CAD | -123.41% |
| 2018 FY | - CAD | -5.14% |
| 2017 Q2 | 539.08 Thousand CAD | -10.89% |
| 2017 Q3 | 613.98 Thousand CAD | 13.89% |
| 2017 Q4 | 328.29 Thousand CAD | -46.53% |
| 2017 FY | - CAD | 176.17% |
| 2017 Q1 | 604.99 Thousand CAD | 128.74% |
| 2016 Q3 | -57.77 Thousand CAD | 93.95% |
| 2016 Q2 | -954.45 Thousand CAD | -347.07% |
| 2016 Q1 | 386.3 Thousand CAD | 155.03% |
| 2016 FY | - CAD | -428.85% |
| 2016 Q4 | -2.1 Million CAD | -3543.25% |
| 2015 Q2 | 368.54 Thousand CAD | 367.45% |
| 2015 Q4 | -701.94 Thousand CAD | -1454.51% |
| 2015 FY | - CAD | -118.86% |
| 2015 Q3 | -45.15 Thousand CAD | -112.25% |
| 2015 Q1 | -137.79 Thousand CAD | 84.01% |
| 2014 Q2 | 528.67 Thousand CAD | -83.6% |
| 2014 Q4 | -861.77 Thousand CAD | -468.04% |
| 2014 Q1 | 3.22 Million CAD | 1574.65% |
| 2014 FY | - CAD | 495.94% |
| 2014 Q3 | -151.71 Thousand CAD | -128.7% |
| 2013 FY | - CAD | 76.49% |
| 2013 Q4 | 192.53 Thousand CAD | -39.69% |
| 2013 Q3 | 319.23 Thousand CAD | 165.85% |
| 2013 Q2 | -484.81 Thousand CAD | 32.56% |
| 2013 Q1 | -718.85 Thousand CAD | 48.88% |
| 2012 Q1 | -730.38 Thousand CAD | 39.78% |
| 2012 FY | - CAD | 9.55% |
| 2012 Q4 | -1.4 Million CAD | -116.28% |
| 2012 Q3 | -650.18 Thousand CAD | -22.97% |
| 2012 Q2 | -528.71 Thousand CAD | 27.61% |
| 2011 Q2 | -357.35 Thousand CAD | 35.56% |
| 2011 FY | - CAD | -3223.17% |
| 2011 Q1 | -554.51 Thousand CAD | 46.99% |
| 2011 Q4 | -1.21 Million CAD | -7.4% |
| 2011 Q3 | -1.12 Million CAD | -216.04% |
| 2010 Q1 | -270.18 Thousand CAD | 65.03% |
| 2010 FY | - CAD | 102.27% |
| 2010 Q4 | -1.04 Million CAD | -311.63% |
| 2010 Q3 | -254.13 Thousand CAD | -117.06% |
| 2010 Q2 | 1.48 Million CAD | 651.37% |
| 2009 FY | - CAD | -35.46% |
| 2009 Q4 | -772.61 Thousand CAD | 31.27% |
| 2009 Q3 | -1.12 Million CAD | 20.58% |
| 2009 Q2 | -1.41 Million CAD | -1.92% |
| 2009 Q1 | -1.38 Million CAD | -69.6% |
| 2008 Q2 | -1.24 Million CAD | -34.56% |
| 2008 Q3 | -720.11 Thousand CAD | 42.08% |
| 2008 FY | - CAD | -7.5% |
| 2008 Q4 | -818.83 Thousand CAD | -13.71% |
| 2008 Q1 | -924 Thousand CAD | 24.45% |
| 2007 Q1 | -389.31 Thousand CAD | 39.63% |
| 2007 Q3 | -990.52 Thousand CAD | -78.73% |
| 2007 Q4 | -1.22 Million CAD | -23.48% |
| 2007 Q2 | -554.19 Thousand CAD | -42.35% |
| 2007 FY | - CAD | -51.82% |
| 2006 FY | - CAD | -19.39% |
| 2006 Q3 | -518.7 Thousand CAD | -5.37% |
| 2006 Q2 | -492.26 Thousand CAD | -18.67% |
| 2006 Q1 | -414.83 Thousand CAD | 56.26% |
| 2006 Q4 | -644.83 Thousand CAD | -24.32% |
| 2005 Q3 | -310.79 Thousand CAD | 1.23% |
| 2005 Q2 | -314.67 Thousand CAD | -98.82% |
| 2005 Q4 | -948.45 Thousand CAD | -205.17% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q1 | -158.26 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 94.99% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 39.97% |
| SQZ Biotechnologies Company | -64.14 Million USD | 94.451% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 79.51% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.785% |
| Mesoblast Limited | -62.38 Million USD | 94.295% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -131.707% |
| Genus plc | 73.7 Million USD | 104.829% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 46.168% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -0.342% |
| Marizyme, Inc. | -34.28 Million USD | 89.618% |
| ContraFect Corporation | -64.99 Million USD | 94.524% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 59.426% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 21.366% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -153.896% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -34.589% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -53.159% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -587.03% |
| Accustem Sciences Inc. | -3.74 Million USD | 4.999% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 92.62% |
| EV Biologics, Inc. | -1.26 Million USD | -180.881% |
| Q BioMed Inc. | -617.62 Thousand USD | -476.258% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 199.64% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -462.792% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -55.795% |
| Biomind Labs Inc. | -1.03 Million USD | -244.027% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 136.035% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 50.3% |
| Skye Bioscience, Inc. | -13.54 Million USD | 73.729% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -139.283% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -14136.52% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 8.372% |
| IMV Inc. | -35.52 Million USD | 89.981% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 77.573% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -42.254% |
| GB Sciences, Inc. | -1.41 Million USD | -150.663% |
| Alpha Cognition Inc. | -9.7 Million USD | 63.329% |
| HST Global, Inc. | -5303.00 USD | -67015.406% |
| CSL Limited | 4.78 Billion USD | 100.074% |
| Halberd Corporation | -74.27 Thousand USD | -4691.57% |
| Enzolytics Inc. | -2.12 Million USD | -67.723% |
| Resverlogix Corp. | -11.74 Million USD | 69.689% |
| Affymax, Inc. | -14.29 Million USD | 75.102% |
| SYBLEU INC | -141.57 Thousand USD | -2414.025% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -16.197% |
| argenx SE | -216.02 Million USD | 98.352% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 93.568% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 392.451% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -137.449% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1039.471% |
| AVAX Technologies, Inc. | -6.11 Million USD | 41.774% |
| Zenith Capital Corp. | -8.6 Million USD | 58.644% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.569% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -20330.113% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -45.481% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1921.953% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 91.021% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -23.054% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -240.16% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 53031.737% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -103.379% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -85.283% |
| BioStem Technologies, Inc. | -7.55 Million USD | 52.882% |
| ONE Bio Corp. | 13.61 Million USD | 126.145% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1865.415% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -73.025% |
| Agentix Corp. | -1.37 Million USD | -159.458% |
| LadRx Corporation | 412.28 Thousand USD | 963.274% |
| Cell Source, Inc. | -4.27 Million USD | 16.697% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -869.207% |
| Regen BioPharma, Inc. | 1.46 Million USD | 342.786% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -279.864% |
| NovAccess Global Inc. | -1.03 Million USD | -243.945% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 140.199% |
| Itoco Inc. | -1.86 Million USD | -90.43% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -837.551% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -218.918% |
| Kadimastem Ltd | -2.62 Million USD | -35.618% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1388.242% |
| CytoDyn Inc. | -18.02 Million USD | 80.259% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -4403.575% |
| Mobile Lads Corp. | -2.24 Million USD | -58.808% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -29004.015% |
| Qrons Inc. | -40.08 Thousand USD | -8779.843% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -632.817% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 774.802% |
| Rebus Holdings, Inc. | -951 Thousand USD | -274.251% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -235.131% |
| International Stem Cell Corporation | 202 Thousand USD | 1861.946% |
| Bioxytran, Inc. | -3.82 Million USD | 6.833% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6661.265% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -44.567% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 90.077% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -7809.178% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -29.99% |
| Neutra Corp. | -181.24 Thousand USD | -1863.69% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 82.345% |
| PureTech Health plc | -11.62 Million USD | 69.389% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 82.343% |
| IXICO plc | -707 Thousand USD | -403.413% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 53.687% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 92.638% |
| CSL Limited | 4.73 Billion USD | 100.075% |
| Cellectis S.A. | -92.63 Million USD | 96.158% |